R&D Systems Intelligence Profile

rndsystems.comLast reviewed: October 20, 2026Research coverage: 91%

Overall data confidence:Unknown

Identity confidence

High

9 of 10 identity fields independently documented

Corporate continuity

Based on domain history and corporate record fields

Regulatory exposure

None identified

Derived from published risk flags

Evidence integrity

High

6 of 7 testing fields documented

Transaction transparency

High

4 of 5 commercial fields documented

Change activity

None tracked

0 change events tracked

Research Incomplete

Research coverage for this vendor is 91%. Our research on R&D Systems remains incomplete — what we have verified so far is published below, and research is continuing.

Still to research:

Payment methods reviewed (accepted_payment_methods)
Public summary reviewed

Overview#

R&D Systems is a Minneapolis, MN brand of Bio-Techne Corporation (Minnesota corporation; Nasdaq: TECH; HQ 614 McKinley Place NE, Minneapolis, MN 55413). FIT WITH CAVEAT: peptides are a minority line — the catalog is dominated by recombinant proteins, antibodies and ELISA kits, with 'Antibody Blocking Peptides' sold as a product grade — but peptides are genuinely sold to buyers, with lot-specific COAs under an ISO 9001:2015 / ISO 13485:2016 quality system. Identity is verified at the parent level; the subsidiary's standalone SoS record and registered agent were not pulled (Unknown). All defined regulatory searches (FDA warning letters — a 'Biotek, Inc.' letter is a different company — recalls, import alerts, FTC enforcement, state AG, civil litigation, criminal/injunctive) returned No Record Found in the defined search. Open items: the August 2026 independent antibody validation-image report (allegation-level), and the pending Merck KGaA acquisition of Bio-Techne (announced 25 June 2026, shareholder-approved, not closed). Accepted payment methods and test recency are Unknown. No High/Critical findings.

Company Identity#

Vendor Brand NameR&D Systems

HighSource: R&D Systems — About Us ('R&D Systems is Part of Bio-Techne'; Minneapolis HQ; legacy dating to 1977)

Primary Website Domainrndsystems.com

ModerateSource: R&D Systems — official website (intake domain confirmation)

Legal Entity NameBio-Techne Corporation (parent); operating subsidiary R&D Systems, Inc. (Minneapolis, MN)

ModerateSource: R&D Systems — About Us ('R&D Systems is Part of Bio-Techne'; Minneapolis HQ; legacy dating to 1977)

State of RegistrationMinnesota

ModerateSource: Bio-Techne Form 10-K text (founded 1976 as Research and Diagnostic Systems, Inc.; public 1985 via Techne merger; Minneapolis HQ properties)

Entity StatusActive — Nasdaq-listed (TECH). Acquisition by Merck KGaA announced 25 June 2026 is pending (shareholder-approved 23 September 2026; not closed as of 2026-10-20).

HighSource: Merck KGaA / Bio-Techne definitive acquisition agreement announcement (2026-06-25)

Incorporation / Formation Date1976 — founded as Research and Diagnostic Systems, Inc.; became public in 1985 through a merger with Techne Corporation (now Bio-Techne Corporation)

ModerateSource: Bio-Techne Form 10-K text (founded 1976 as Research and Diagnostic Systems, Inc.; public 1985 via Techne merger; Minneapolis HQ properties)

Named Principals / ManagersKim Kelderman — President and Chief Executive Officer, Bio-Techne Corporation

HighSource: Bio-Techne investor relations — FY2026 results release (Kim Kelderman, President and CEO)

Registered AgentNot independently verified

UnknownSource: Bio-Techne Form 10-K text (founded 1976 as Research and Diagnostic Systems, Inc.; public 1985 via Techne merger; Minneapolis HQ properties)

Operating Address614 McKinley Place NE, Minneapolis, MN 55413, USA (Bio-Techne / R&D Systems headquarters)

HighSource: Bio-Techne — GMP protein product page (lot-specific COA; ISO 9001:2015 / ISO 13485:2016 QMS; HQ contact details)

Address ConsistencyConsistent — the Minneapolis HQ address is stable across Bio-Techne's 10-K property disclosures (owned ~800,000 sq ft Minneapolis headquarters complex occupied by the R&D Systems subsidiary, plus a St. Paul facility) and current product/contact pages.

ModerateSource: Bio-Techne Form 10-K text (founded 1976 as Research and Diagnostic Systems, Inc.; public 1985 via Techne merger; Minneapolis HQ properties)

Domain and Digital Identity#

Domain Registration Date1995-07-29

HighSource: Verisign RDAP — rndsystems.com

Domain Ownership / Registrar Change HistoryRegistrar: GoDaddy.com, LLC; RDAP record last changed 2026-07-14; registration runs to 2031-07-28; registrant redacted. One of the earliest vendor domains in this directory (1995); no transfer or impersonation signals.

ModerateSource: Verisign RDAP — rndsystems.com

Website Continuityrndsystems.com is live and actively maintained (current About page; © 2026 R&D Systems, Inc.); the product catalog and product documents (COA/SDS) are increasingly served through bio-techne.com.

ModerateSource: R&D Systems — About Us ('R&D Systems is Part of Bio-Techne'; Minneapolis HQ; legacy dating to 1977)

Contact Channel IntegrityPublished HQ phone 612-379-2956 and toll-free 800-343-7475 on official Bio-Techne product/contact pages; support via rndsystems.com and bio-techne.com. No conflicting third-party contact details identified.

ModerateSource: Bio-Techne — GMP protein product page (lot-specific COA; ISO 9001:2015 / ISO 13485:2016 QMS; HQ contact details)

Regulatory and Legal History#

FDA Warning Letter HistoryNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

FDA Recall / Safety Action HistoryNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

FDA Import Alert / Detention ExposureNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

FTC Enforcement HistoryNo Record Found in the defined search — no FTC enforcement action names Bio-Techne or R&D Systems as a respondent. Note: Bio-Techne's pending sale to Merck KGaA underwent FTC merger review in 2026 (the parties withdrew and refiled their HSR notification in August 2026 to allow more review time; the waiting period expired 18 September 2026) — merger review of the vendor's own acquisition, not an enforcement action against it.

ModerateSource: Law360 — Bio-Techne gives FTC more time on $11.3B Merck KGaA deal (HSR withdraw/refile, Aug 2026)

State Regulatory / Attorney General ActionsNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

Relevant Civil LitigationNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

Criminal / Injunctive ProceedingsNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

Testing and COA Evidence#

Public COA AvailabilityLot-specific Certificates of Analysis and SDS documents are published per product (served via bio-techne.com product pages); Bio-Techne states each product is provided with a lot-specific COA including specifications and test results.

ModerateSource: Bio-Techne — GMP protein product page (lot-specific COA; ISO 9001:2015 / ISO 13485:2016 QMS; HQ contact details)

Batch / Lot SpecificityCOAs are lot-specific (specifications and test results per lot) per the vendor's product documentation practice.

ModerateSource: Bio-Techne — GMP protein product page (lot-specific COA; ISO 9001:2015 / ISO 13485:2016 QMS; HQ contact details)

Independent Laboratory IdentityIn-house QC under an ISO 9001:2015 and ISO 13485:2016 certified quality management system (stated for GMP protein manufacture and testing); no independent third-party laboratory is named.

ModerateSource: Bio-Techne — GMP protein product page (lot-specific COA; ISO 9001:2015 / ISO 13485:2016 QMS; HQ contact details)

COA Verification StatusCOAs are retrievable from official product pages by product/lot; no third-party verification service identified.

ModerateSource: Bio-Techne — GMP protein product page (lot-specific COA; ISO 9001:2015 / ISO 13485:2016 QMS; HQ contact details)

Test RecencyNot independently verified

UnknownSource: Bio-Techne — GMP protein product page (lot-specific COA; ISO 9001:2015 / ISO 13485:2016 QMS; HQ contact details)

Testing CoveragePeptides are a minority line: 'Antibody Blocking Peptides' is offered as a product grade across the catalog, within a range dominated by recombinant proteins, antibodies and ELISA kits (the brand claims an extensive catalog; Bio-Techne brands together claim 500,000+ products). Each product is supplied with lot-specific COA documentation.

ModerateSource: R&D Systems — About Us ('R&D Systems is Part of Bio-Techne'; Minneapolis HQ; legacy dating to 1977)

Evidence ConsistencyR&D Systems (Bio-Techne) is named in the August 2026 independent research-integrity report (Reese Richardson) covering 15 vendors' antibody validation images; per coverage of the report, Bio-Techne did not comment on third-party manufacturing. Allegation-level independent reporting (antibodies, not peptides), not a regulatory finding.

ModerateSource: C&EN — New report suggests widespread image manipulation in antibody market (Aug 2026)

Payment, Refund and Shipping#

Accepted Payment MethodsNot independently verified

UnknownSource: Bio-Techne Terms and Conditions of Sale (via Tocris Bioscience brand site — returns: RA within 10 business days; 30-day returns; 14-day non-delivery reporting)

Refund / Return PolicyBio-Techne Terms and Conditions of Sale: returns are accepted for damaged or defective products; a Return Authorization is required — Customer Service must be contacted within 10 business days of receipt; returns must be made within 30 calendar days in original containers; non-delivery must be reported within 14 calendar days of the invoice date.

ModerateSource: Bio-Techne Terms and Conditions of Sale (via Tocris Bioscience brand site — returns: RA within 10 business days; 30-day returns; 14-day non-delivery reporting)

Shipping & Fulfillment RepresentationsFulfillment is governed by Bio-Techne's terms of sale (including the 14-day non-delivery reporting window); carrier and cold-chain specifics were not captured in this pass.

LowSource: Bio-Techne Terms and Conditions of Sale (via Tocris Bioscience brand site — returns: RA within 10 business days; 30-day returns; 14-day non-delivery reporting)

Terms / Policy StabilityTerms of sale are published across Bio-Techne brand sites (e.g., Tocris) in a common format; no abrupt changes observed in this intake pass.

LowSource: Bio-Techne Terms and Conditions of Sale (via Tocris Bioscience brand site — returns: RA within 10 business days; 30-day returns; 14-day non-delivery reporting)

Customer Complaint PatternNo concentrated fulfillment or fraud complaint pattern identified in the defined search; the prominent 2026 criticism is the antibody validation-image report (see evidence_consistency).

ModerateSource: C&EN — New report suggests widespread image manipulation in antibody market (Aug 2026)

Material Changes#

No material changes recorded.

Sources#

R&D Systems — official website (intake domain confirmation)Tier 2 · Official/CommercialVendor Website

Retrieved: October 20, 2026